The Beijing plant, a joint venture between Sisram Medical (Tianjin) and Sinmait Medical Technology, adopts the company’s established Israeli manufacturing standards and quality control protocols. By integrating these workflows with the domestic supply chain provided by Fosun Pharma, Sisram aims to stabilize product delivery and enhance after-sales responsiveness across the Chinese market.
Jiahong Li, Co-CEO and CFO of Sisram, stated that the facility serves as a core engine for regional growth. Beyond meeting domestic demand for anti-aging and skin rejuvenation technology, the plant is designed to support wider expansion across the Asia-Pacific region. The company intends to leverage this site to create a more resilient industrial ecosystem, allowing for faster iteration of its Energy-Based Devices and a deeper integration of its aesthetic product portfolio.
Comments (0)
No comments yet. Be the first!